Impact of phototherapy on selected lipid metabolism indices and oxidation markers in patients with psoriasis vulgaris

Postepy Dermatologii i Alergologii

Volumn 28, Issue 2, 2011, Pages 83-91

  Hadas, Ewa ^a   Świȩtochowska, Elzbieta ^a   Wielkoszyński, Tomasz ^a   Jaroszewska Smoleń, Jagoda ^a   Jarza̧b, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Autoantibodies against oxLDL; Ferric reducing ability of plasma; Oxidatively modified low density lipoprotein; Phototherapy; Psoriasis

Indexed keywords

ANTIOXIDANT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; TRIACYLGLYCEROL;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; LIPID METABOLISM; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PHOTOTHERAPY; PSORIASIS VULGARIS; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAVIOLET A RADIATION; ULTRAVIOLET B 311 RADIATION; ULTRAVIOLET B RADIATION;

EID: 79955639167     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Badsgard O, Fisher G, Voorhees JJ, Cooper KD. The role of immune system in the pathogenesis of psoriasis. J Invest Dermatol 1990; 95: 32-34.
2. Cooper KD. Psoriasis. Leukocytes and cytokines. Dermatol Clin 1990; 8: 737-45.
3. Uyanik BS, Ari Z, Onur E, et al. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002; 40: 65-8. (Pubitemid 34196452)
4. Seçkin D, Tokgözoǧlu L, Akkaya S. Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol 1994; 31: 445-9.
5. Vahlquist C, Michaëlsson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol (Stockh) 1987; 67: 12-5. (Pubitemid 17003486)
6. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dislipidemia and oxidative stress in mild and severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-9. (Pubitemid 32121803)
7. Hadas E, Bożek A, Jarza̧b J. Wpływ fototerapii na wybrane wskaźniki profilu lipidowego u chorych na łuszczycȩ zwykła z uwzglȩdnieniem nasilenia procesu chorobowego. Post Dermatol Alergol 2007; XXIV: 215-24.
8. Komorowska O, Grabińska K, Szczerkowska-Dobosz A, Maciejewska A. Zespół metaboliczny w łuszczycy. Dermatol Klin 2008; 10: 227-30.
9. Saraceno R, Ruzzetti M, De Martino MU, et al. Does metabolic syndrome influence psoriasis? Rev Med Pharmacol Sci 2008; 12: 339-41.
10. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-6.
11. Offidani AM, Ferretti G, Taus M, et al. Lipoprotein peroxidation in adult psoriatic patients. Acta Derm Venereol (Stockh) 1994; 186 (Suppl): 38-40. (Pubitemid 24208148)
12. Örem A, Çimşit G, Deǧer O, et al. The significance of autoantibodies against oxidatively modified low density lipoprotein (LDL) in patients with psoriasis. Clin Chim Acta 1999; 284: 81-8. (Pubitemid 29324867)
13. Wojas-Pelc A, Rajzer L, Rajzer M. Nieprawidłowości w badaniu echokardiograficznym u pacjentów z łuszczyca̧. Przegl Dermatol 2005; 92: 119-24. (Pubitemid 40686213)
14. Çimşit G, Örem A, Deǧer O, et al. The variation of serum lipoprotein (a) level with disease activity in psoriasis. Br J Dermatol 1998; 138: 917-9.
15. Kural BV, Örem A, Çimşit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328: 71-82. (Pubitemid 36135781)
16. Pietrzak A, Lecewicz-Toruń B. Activity of serum lipase (EC 3.1.1.3) and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002; 8: 9-13.
17. Vaarala O, Alfthan G, Jauhianinen N, et al. Crossreaction between antibodies to oxidized low density lipoprotein and cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-5. (Pubitemid 23109111)
18. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profil In psoriasis: a controlled study. Dermatol Venereol 2007; 21: 1330-2. (Pubitemid 350020138)
19. Sakurai K, Sawamura T. Stress and vascular responses: endothelial dysfunction via lecitin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci 2003; 91: 182-6. (Pubitemid 36575574)
20. Brigant S, Picardo M. Co nowego wiadomo na temat działalnoś ci antyoksydantów i peroksydacji lipidów w chorobach skóry. Dermatologica 2004; 21: 12-9.
21. Ciebiada M, Pietras T, Górski P. Stres oksydacyjny w chorobach skóry. Post Dermatol Alergol 2002; 2: 90-8.
22. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12. (Pubitemid 38228462)
23. Wilkinson DI. Psoriasis and dietary fat: the fatty acid composition of surface and scale (ether-soluble) lipids. J Invest Dermatol 1966; 3: 185-91.
24. Wu-Pong S, Elias PM, Feingold KR. Influence of altered serum cholesterol levels and fasting on cutaneous cholesterol synthesis. J Invest Dermatol 1994; 102: 799-803.
25. Bhakdi S. An hypothesis for the immunopathogenesis of atherosclerosis. Clin Nephrol 2003; 60: 49-52.
26. Penn MS, Chisolm GM. Oxidized lipoproteins altered cell function in atherosclerosis. Atherosclerosis. 1994; 108 (Suppl): 21-9.
27. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; 109 (23 Suppl 1): 2-7.
28. Cheng HM, Sundram K. Oxidized LDL, diet and natural antibodies. Am J Clin Nutr 1999; 70: 104-13.
29. Seccia M, Albano E, Maggi E, Bellomo G. Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vitro independently from lipid peroxidation. Arterioscler Thromb Vasc Biol 1997; 17: 134-40.
30. Benzie FF, Strain JJ. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. In: Oxidants and antioxidants. Part Packer AL (ed.) Academic Press, San Diego 1999; 15-28.
31. Benzie FF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Ann Biochem 1996; 239: 70-6.
32. Pourzand C, Tyrrell RM. Apoptosis, the role of oxidative stress and the example of solar UV radiation. Photochem Photobiol 1999; 70: 308-90.
33. Godar DE. Preprogrammed and programmed cell death mechanisms of apoptosis: UV-induced immediate and delayed apoptosis. Photochem Photobiol 1996; 63: 825-30. (Pubitemid 126467647)
34. Godar DE. UVA 1 radiation triggers two different final apoptopic pathways. J Invest Dermatol 1999; 112: 3-12. (Pubitemid 29024698)
35. Zarȩbska Z. Immunologiczne aspekty fototerapii. Post Hig Med Dośw 2002; 56: 139-53.
36. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III). JAMA 2001; 269: 3015-23.
37. Podsumowanie Trzeciego Raportu Zespołu Ekspertów Narodowego Programu Edukacyjnego na temat Profilaktyki Cholesterolowej (NCEP) do spraw Wykrywania, Oceny i Leczenia Zwiȩkszonego Stȩżenia Cholesterolu we Krwi u Osób Dorosłych. JAMA (ed. pol.). 2001; 3: 489-505.
38. Kemeny L, Ruzicka T, Braun-Falco O. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 1990; 3: 1-20. (Pubitemid 20242147)
39. Timmerman MG, Mier PD, van de Kerkhof PC. Studies on the time course of dithranol-induced inflammation by quantification of alkaline phosphatase. Acta Derm Venereol 1990; 70: 66-9. (Pubitemid 20088395)
40. Peus D, Beyerle A, Rittner HL. Antipsoriatic drug anthralin activates JNK via lipid peroxidation: mononuclear cells are more sensitive than keratinocites. J Invest Dermatol 2000; 114: 688-92. (Pubitemid 30227001)
41. Coimbra S, Oliveira H, Reis F, et al. Psoriasis therapy and cardiovasular risk factor: a 12-week follow-up study. Am J Clin Dermatol 2010; 11: 423-2.
42. Abel EA. Phototherapy: UVB and PUVA. Cutis 1999; 64: 339-42.
43. Kaszuba A. Leczenie ogólne łuszczycy. Medipress Dermatol 2000; 5: 3-15.